Some aspects of the in vitro oxidation of 35S-chlorpromazine.
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D002746:Chlorpromazine / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002855:Chromatography, Thin Layer; D003300:Copper / Q000494:pharmacology; D003543:Cysteamine / Q000494:pharmacology; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003840:Deoxycholic Acid / Q000494:pharmacology; D004229:Dithiothreitol / Q000494:pharmacology; D004790:Enzyme Induction / Q000187:drug effects; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008628:Mercury / Q000494:pharmacology; D008862:Microsomes, Liver / Q000201:enzymology; D009928:Organ Specificity; D010084:Oxidation-Reduction; D013045:Species Specificity; D013056:Spectrophotometry, Ultraviolet; D013462:Sulfur Radioisotopes; D013997:Time Factors
D000975:Antioxidants; D013462:Sulfur Radioisotopes; D003840:Deoxycholic Acid; D003543:Cysteamine; D003300:Copper; D003577:Cytochrome P-450 Enzyme System; D008628:Mercury; D004229:Dithiothreitol; D002746:Chlorpromazine